autologous bone marrow derived mononuclear cells

Autologous bone marrow derived mononuclear cells (BMMNCs or ABMMCs) are a heterogeneous population of cells isolated from a patient's own bone marrow. This population includes hematopoietic stem and progenitor cells, lymphoid cells, monocytes, and mesenchymal stem/stromal cells[1][6]. These cells are separated by density gradient centrifugation after bone marrow aspiration, typically from the posterior iliac crest[1][6]. The mechanism of action is multimodal and not target-specific; BMMNCs are believed to exert therapeutic effects mainly through paracrine signaling, modulation of inflammation, immune regulation, promotion of angiogenesis, and potentially tissue regeneration[1][3][6][7]. Clinical studies have investigated or implemented autologous BMMNC therapy in indications such as critical limb ischemia, peripheral arterial disease, heart failure (ischemic and non-ischemic), autism spectrum disorder, severe asthma, and other refractory conditions[3][4][5][6]. BMMNCs have been administered through various routes depending on the indication, including intravascular (intracoronary, intravenous), intrathecal, and local tissue injections[4][5][6]. The use of autologous cells reduces risk of immunogenicity and graft-versus-host disease compared to allogeneic products[2].

Other names

BMMNCABMMCbone marrow mononuclear cellsbone marrow-derived mononuclear cells